Abstract:While an increased incidence of thromboembolic events and hypercoagulability during acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been well described,[1] [2] arterial thrombosis post COVID-19 (coronavirus disease 2019), although uncommon, has yet to be recognized as part of the late sequelae of COVID-19 (i.e., "long COVID") by the Centers for Disease Control and Prevention (CDC) in their guidance of "Late Sequelae of COVID-19" under the Clinical Care Guidance for Healthcare Professionals about Coronavirus (COVID-19),[3] or by the National Institute for Health and Care Excellence (NICE) in recently published living guidelines on post–acute COVID-19.[4] This is, despite the emerging reports of post COVID-19 arterial thrombosis, particularly in patients without cardiovascular risk factors.[5] [6] [7] [8] [9] In a preprint study[10] evaluating the incidence of neurological and psychiatric sequelae in 6 months in 236,379 post COVID-19 survivors, the authors noted an increased risk of cerebrovascular events, with higher hazard ratio in most diagnostic categories than after influenza or other respiratory infections. A high incidence of stroke was found, as high as 1:10 (or 3% in patients with first episode of stroke) in patients who had previously experienced delirium or altered mental state. Moreover, it was noted that the incidence of these complications was increased even in individuals who had not required hospitalization. In a case series on delayed arterial thrombosis post COVID-19,[5] we described four cases in young males (aged <40 years) with previous asymptomatic SARS-CoV-2 infection, and lack of preexisting cardiovascular risk factors. These patients presented with a median of 78 days from positive SARS-CoV-2 total antibody positivity to thrombotic event with catastrophic strokes, acute myocardial infarction, and acute ischemic limb. Standard thrombophilia workup (including tests for antiphospholipid syndrome, protein C, protein S, antithrombin levels, and factor V Leiden mutation) was negative, with von Willebrand factor (VWF) and D-dimer levels remaining persistently elevated weeks after their initial thrombotic event. Our observations suggest that the SARS-CoV-2 virus poses significant chronic immuno-thrombogenicity which may cumulate eventually in a major thrombotic event that occurs unexpectedly many weeks later in fit patients with mild or asymptomatic COVID-19 infection. Sustained prothrombotic changes in COVID-19 patients were found in a separate study,[11] with increased thrombin generation, decreased plasma fibrinolysis, elevated factor VIII, VWF, and plasminogen activator inhibitor-1 (PAI-1) levels on admission and 4 months after discharge, suggestive of platelet activation and ongoing intravascular coagulation. Several other case reports highlight the phenomena of post COVID-19 arterial events as well. Notably, two case reports demonstrated the development of late, lower extremity, multilevel arterial thrombosis in a 24-year-old male and a 54-year-old male, both with nonsevere COVID-19 and without previous significant medical histories.[6] [7] A previously healthy 61-year-old female with COVID-19 not requiring hospitalization presented 32 days later with fatal main pulmonary artery thrombosis discovered on autopsy.[8] Although pulmonary artery thrombosis is often considered a form of venous thrombosis, as the occlusion can result from emboli arising from a deep vein thrombosis, we make a point here that (1) this will still terminate in the pulmonary arteries and not pulmonary veins and (2) that in COVID-19, pulmonary thromboses are thought to originate in the pulmonary arteries/vasculature.[12] Also, a 35-year-old male with a medical history of mild-intermittent asthma and obesity presented 49 days after the onset of flu-like illness not requiring hospitalization (SARS-CoV-2 antibodies were positive on day 2 of admission) with extensive thrombosis including a large left ventricle thrombus, right coronary artery thrombosis, and a middle cerebral artery thrombosis.[9] In summary, these post COVID-19 cases, most of who were young and with no evident cardiovascular risk factors, developed delayed, massive arterial thromboses.Although post thrombotic events are known to occur after acute viral infections such as influenza,[13] [14] where up to a third of acute myocardial infar -Abstract Truncated-

Severe arterial thrombosis associated with Covid-19 infection

Aortic thrombosis as a dramatic vascular complication in COVID-19 disease

Acute Lower-Extremity Ischemia in a Patient with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients

High Prevalence of Deep Venous Thrombosis in Non-Severe COVID-19 Patients Hospitalized for a Neurovascular Disease

A review of pathophysiological mechanism, diagnosis, and treatment of thrombosis risk associated with COVID-19 infection

Lower extremity arterial thrombosis associated with COVID-19 is characterized by greater thrombus burden and increased rate of amputation and death

The Risk of Thrombosis after Acute-Covid-19 Infection

A COVID-19 Patient with Simultaneous Renal Infarct, Splenic Infarct and Aortic Thrombosis during the Severe Disease

Clinical features of thrombosis and bleeding in COVID-19

COVID-19-related Peripheral Arterial Thrombosis Treated in a Large Health Maintenance Organization

High incidence of venous thrombosis in patients with moderate-to-severe COVID-19

Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies

Post COVID-19 Arterial Thromboembolism: A Clear and Present Danger

Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis

Acute arterial occlusion of the lower limb as the main clinical manifestation in a patient with Covid-19 - Case Report

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 Infection

Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review

Management of acute aortoiliac arterial thrombosis in patients with the novel coronavirus disease 2019: A case series and systematic review of the literature

Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan